Alzheimer’s disease is a progressive brain disease that destroys memory, thinking ability, and eventually the capacity to carry out basic daily tasks. It is the most common cause of dementia, and an estimated 7.1 million Americans are currently living with symptoms. That number is projected to nearly double to 13.9 million by 2060. Worldwide, more than 50 million people live with some form of dementia.
What Happens Inside the Brain
Alzheimer’s involves two hallmark problems in the brain: clumps of a protein called beta-amyloid that build up between nerve cells, and tangled fibers of another protein called tau that form inside them. Beta-amyloid fragments, particularly small clusters called oligomers, latch onto receptors on the surface of nerve cells at the junctions where they communicate with each other. This binding triggers a cascade of damage: genes inside the cell get switched on in harmful ways, inflammation spreads through surrounding tissue, and the connections between neurons begin to break down.
Tau protein normally helps stabilize the internal structure of neurons, like rungs holding a ladder together. In Alzheimer’s, tau becomes chemically altered and collapses into tangles, which disrupts the cell’s ability to transport nutrients and signals. As both processes advance, neurons die in growing numbers, and the brain physically shrinks. The damage typically starts in areas involved in memory formation and gradually spreads to regions that control language, reasoning, and eventually basic body functions like swallowing and walking.
Normal Forgetfulness vs. Early Warning Signs
Everyone forgets things occasionally, and some slowing of memory retrieval is a normal part of aging. You might forget which day it is but remember later, or occasionally lose your keys. These are signs of mild, routine forgetfulness. Alzheimer’s is different: the memory problems are persistent and disruptive enough to interfere with daily life.
Some specific contrasts help illustrate the difference:
- Normal aging: Making a bad decision once in a while. Alzheimer’s: Making poor judgments and decisions frequently.
- Normal aging: Missing a monthly payment. Alzheimer’s: Consistent trouble managing bills.
- Normal aging: Sometimes forgetting which word to use. Alzheimer’s: Difficulty holding a conversation.
- Normal aging: Losing things from time to time. Alzheimer’s: Misplacing things often and being unable to retrace steps to find them.
There’s also a middle ground called mild cognitive impairment (MCI), where memory or thinking problems are noticeable and measurable but don’t yet interfere with daily independence. MCI can be an early sign of Alzheimer’s, but not everyone who has it will progress to dementia.
Red flags worth discussing with a doctor include asking the same questions repeatedly, getting lost in familiar places, growing confusion about time or people, trouble following recipes or directions, and neglecting self-care like bathing or eating properly.
Stages and How Symptoms Progress
Alzheimer’s moves through three broad clinical stages, though the boundaries between them aren’t always sharp.
Mild (Early) Stage
People in this stage can still live independently. The most common symptom is mild forgetfulness, particularly for recent events and new information. You might notice trouble remembering names, misplacing valuable items, difficulty making plans, or problems staying organized and managing money. The person is often aware something is off, and friends and family may start to notice too.
Moderate (Middle) Stage
This is typically the longest stage, lasting many years. Memory gaps deepen: the person may have increasing trouble remembering events, learning new things, or handling complex tasks like planning a dinner. They may still recall details about their own life, like their address, but forget names of close family members. Reading, writing, and working with numbers become harder. Personality changes can emerge, including mood swings, withdrawal, paranoia, hallucinations, and agitation, particularly in the late afternoon or evening. Sleep problems and wandering away from home become real concerns. Help with daily tasks like choosing clothing and brushing teeth becomes necessary.
Severe (Late) Stage
In the final stage, people lose most physical abilities, including walking, sitting, and eating. Bowel and bladder control is often lost. They may say isolated words or phrases but can no longer hold a conversation, and awareness of surroundings fades almost entirely. Vulnerability to infections rises sharply, with pneumonia being a common and serious risk. Full-time assistance with all activities is required.
Causes and Genetic Risk Factors
For most people, Alzheimer’s results from a combination of genetic susceptibility, lifestyle factors, and aging. The strongest known genetic influence on the common, late-onset form is a gene called APOE, which comes in three main variants. APOE ε3 is the most common and appears to have a neutral effect. APOE ε4, carried by roughly 15% to 25% of the population, increases risk and is associated with earlier onset. About 2% to 5% of people carry two copies of ε4, which raises risk further. APOE ε2, found in 5% to 10% of people, appears to offer some protection.
A small number of Alzheimer’s cases, typically striking before age 65, are caused by rare inherited mutations in one of three genes: APP, PSEN1, or PSEN2. If a parent carries one of these variants, each child has a very strong probability of developing the disease, often well before age 65. These cases are sometimes called early-onset or younger-onset Alzheimer’s, and they account for a small fraction of all diagnoses.
Modifiable Risk Factors
A 2020 Lancet Commission report identified 12 lifestyle and health factors linked to dementia risk, spread across the lifespan. In early life, limited education is a risk factor. In midlife, the key risks are hearing loss, traumatic brain injury, high blood pressure, excessive alcohol use, and obesity. In later life, smoking, depression, social isolation, physical inactivity, diabetes, and air pollution exposure all contribute. Hypertension alone affects roughly 20% to 24% of adults, and hearing loss affects about 10% to 12%, making these two among the most prevalent modifiable contributors at the population level.
None of these factors guarantee Alzheimer’s, and addressing them doesn’t guarantee prevention. But collectively, they represent a meaningful opportunity to lower risk, particularly when action starts early and spans multiple areas.
How Alzheimer’s Is Diagnosed
Alzheimer’s diagnosis has changed significantly. Revised criteria published in 2024 define the disease by its biology rather than its symptoms. Under this framework, a diagnosis can be made based on a single positive biomarker test for amyloid protein, even if the person has no symptoms yet. This reflects the understanding that Alzheimer’s exists on a continuum, with brain changes beginning years or even decades before memory problems appear.
In practice, the diagnostic tools include brain imaging scans that detect amyloid and tau deposits, spinal fluid tests that measure protein ratios, and increasingly, blood tests. A blood marker called p-tau217 now performs at levels comparable to spinal fluid analysis, making biological diagnosis more accessible than it has ever been. Spinal fluid tests for amyloid identify the disease with 85% to 92% sensitivity and 89% to 94% specificity. These biomarker-based approaches are especially important because similar symptoms can result from non-Alzheimer’s causes, meaning memory loss alone isn’t enough to confirm the diagnosis.
Current Treatment Options
There is no cure for Alzheimer’s, but treatment options have expanded. Older medications help manage symptoms by boosting chemical signaling between surviving neurons, which can temporarily improve memory and thinking. These drugs don’t slow the underlying disease.
A newer class of treatments targets amyloid plaques directly. The FDA has approved two antibody-based drugs, lecanemab and donanemab, that work by clearing amyloid buildup from the brain. Donanemab is given as an intravenous infusion every four weeks and is approved for people in the mild cognitive impairment or mild dementia stage. These treatments can modestly slow cognitive decline, but they come with risks including brain swelling and small brain bleeds that require regular monitoring with brain scans. They represent the first therapies that address the biological process of the disease rather than just its symptoms.
The Burden on Families and Caregivers
Alzheimer’s places an enormous strain on families. Unpaid caregivers, most of them family members, provide the equivalent of nearly $470 billion a year in free care in the United States. Almost one-third of dementia caregivers spend 20 or more hours per week providing care. The average out-of-pocket cost for dementia caregivers runs about $9,000 per year, higher than the $7,200 average for caregivers of people with other conditions. Beyond the financial toll, caregiving for someone with Alzheimer’s is associated with higher rates of depression, anxiety, and physical health problems in the caregivers themselves.